Bionano Genomics yesterday morning said the role of its Chief Financial Officer, Gulsen Kama, was impacted by its workforce reduction and that Kama will no longer be employed with the company effective September 18. On September 4, R. Erik Holmlin, President and Chief Executive Officer of the company, was appointed by the board to serve as the principal financial officer of the company, effective September 18. Mark Adamchak, Vice President of Accounting & Finance was appointed to serve as the principal accounting officer of the company, effective September 18. Holmlin and Adamchak will continue to serve in these roles until the company appoints a new Chief Financial Officer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Genomics downgraded to Neutral from Buy at BTIG
- BioNano Genomics Restructures for Cost Efficiency and Cash Flow Optimization
- Bionano Genomics downgraded at Scotiabank on limited capital market visibility
- Bionano Genomics downgraded to Sector Perform from Outperform at Scotiabank
- Bionano Genomics price target lowered to $5.20 from $6.80 at Ladenburg